Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 9/20 | 0.64 |
| ▸ | PDE3A | Q14432 | 9/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | MAOA | P21397 | 1/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.64 |
| ▸ | F10 | P00742 | 1/20 | 0.61 |
| ▸ | PDE4A | P27815 | 3/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5952845 | 0.87 | PDE3B (0.66) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Meribendan SCHEMBL892301 | 0.82 | PDE3B (0.70) | PDE3BPDE3AABCB11MAOAADORA2A | |
| SCHEMBL10463603 | 0.82 | PDE3B (0.68) | PDE3BPDE3AABCB11MAOAADORA2A | |
| SCHEMBL10769323 | 0.81 | PDE3B (0.72) | PDE3BPDE3AABCB11MAOAADORA2A | |
| SCHEMBL9516148 | 0.81 | PDE3B (0.67) | PDE3BPDE3AABCB11MAOAADORA2A | |
| SCHEMBL16157203 | 0.81 | PDE3B (0.67) | PDE3BPDE3AABCB11MAOAADORA2A | |
| SCHEMBL9781456 | 0.80 | PDE3B (0.77) | PDE3BPDE3AABCB11MAOAADORA2A | |
| SCHEMBL8264681 | 0.80 | PDE3B (0.77) | PDE3BPDE3AABCB11MAOAADORA2A | |
| SCHEMBL10922011 | 0.80 | PDE3B (0.66) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Hydrochloric Acid SCHEMBL9781446 | 0.80 | PDE3B (0.66) | PDE3BPDE3AABCB11MAOAADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | claimed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | claimed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | claimed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | claimed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | PDE3B 217/4885PDE3A 261/4885ABCB11 598/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | PDE3B 323/4885PDE3A 328/4885ABCB11 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.